Abstract

Moisés A. Franco-Molina*, Edgar Mendoza-Gamboa, Diana F. Miranda-Hernández, Crystel A. Sierra-Rivera, Pablo Zapata-Benavides, Magda E. Vera-García, Reyes S. Tamez-Guerra and Cristina Rodríguez-Padilla

IMMUNEPOTENT CRP is a mixture of low molecular weight substances, some of which have been shown to be clinically effective for a broad spectrum of diseases, maintaining the immune system and increasing the quality of life of the patients. To determine whether IMMUNEPOTENT CRP modulates the antioxidant and anti-inflammatory effects in LPS-stimulated human macrophages; U-937 cells were differentiated to macrophages with PMA (10 ng/mL), stimulated with LPS (50 ng/mL), and treated with IMMUNEPOTENT CRP (0, 0.5, 1, 3, and 5 U/mL). Thereafter, the antioxidant (Total antioxidant, CAT, GPx, and SOD), inflammatory (NO, TNF-α, COX-2, PGD2), IκB phosphorylation, and NF-κB DNA binding activities were evaluated by ELISA and colorimetric enzymatic assays. The IMMUNEPOTENT CRP significantly increased the Total antioxidant, CAT, GPx, and SOD activities, and significantly decreased the NO, and TNF-α production, COX-2 and PGD2 activities, IκB phosphorylation, NF-κB p50 and p65 subunit DNA binding activity in LPS-stimulated human macrophages (*P<0.05). Our results demonstrated that IMMUNEPOTENT CRP plays an important role in modulating the antioxidant and antiinflammatory effects through IκB/NF-κB pathway in LPS-stimulated human macrophages, suggesting that IMMUNEPOTENT CRP is an effective therapeutic agent in process involved in oxidative cellular damage and clinical inflammatory diseases.